These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 3332119

  • 1. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies.
    Ringdén O, Bäckman L, Lönnqvist B, Heimdahl A, Lindholm A, Bolme P, Gahrton G.
    Bone Marrow Transplant; 1986 May; 1(1):41-51. PubMed ID: 3332119
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J, Ringdén O.
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [Abstract] [Full Text] [Related]

  • 3. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy.
    Aschan J, Ringdén O, Sundberg B, Gahrton G, Ljungman P, Winiarski J.
    Bone Marrow Transplant; 1991 Feb; 7(2):113-9. PubMed ID: 2049554
    [Abstract] [Full Text] [Related]

  • 4. An increased risk of relapse in cyclosporin-treated compared with methotrexate-treated patients: long-term follow-up of a randomized trial.
    Bäckman L, Ringdén O, Tollemar J, Lönnqvist B.
    Bone Marrow Transplant; 1988 Sep; 3(5):463-71. PubMed ID: 2847843
    [Abstract] [Full Text] [Related]

  • 5. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.
    Ringdén O, Klaesson S, Sundberg B, Ljungman P, Lönnqvist B, Persson U.
    Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946
    [Abstract] [Full Text] [Related]

  • 6. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M, Mousavi A, Gholibeikian S, Bahar B, Samiee S, Ashouri A, Eghbal L, Ghavamzadeh A.
    Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporin A in marrow transplantation for leukemia and aplastic anemia.
    Bacigalupo A, Frassoni F, van Lint MT, Raffo MR, Vitale V, Corbetta G, Chierichetti S, Marmont AM.
    Exp Hematol; 1985 May; 13(4):244-8. PubMed ID: 3886417
    [Abstract] [Full Text] [Related]

  • 9. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients.
    Ringdén O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P, Lönnqvist B, Tollemar J, Janossy G, Sundberg B.
    Bone Marrow Transplant; 1991 Mar; 7(3):221-6. PubMed ID: 2059758
    [Abstract] [Full Text] [Related]

  • 10. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 11. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y, Nagatoshi Y, Kawano Y, Okamura J.
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [Abstract] [Full Text] [Related]

  • 12. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Ferrant A, Latinne D, Bazin H, Straetmans N, Cornet A, de la Parra B, Michaux JL.
    Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
    [Abstract] [Full Text] [Related]

  • 13. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [Abstract] [Full Text] [Related]

  • 14. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
    Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Kawase T, Muramatsu H, Morishima Y, Kodera Y.
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, Rondelli D, Mangianti S, Motta MR, Rizzi S, Tassi C, Cavo M, Remiddi C, Curti A, Conte R, Tura S.
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [Abstract] [Full Text] [Related]

  • 16. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.
    Mrsić M, Labar B, Bogdanić V, Nemet D, Pavletić Z, Plavsić F, Dobrić I, Marusić M, Francetić I, Kastelan A.
    Bone Marrow Transplant; 1990 Aug; 6(2):137-41. PubMed ID: 2207450
    [Abstract] [Full Text] [Related]

  • 17. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC.
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [Abstract] [Full Text] [Related]

  • 18. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
    Aschan J, Ringdén O, Andström E, Ljungman P, Lönnqvist B, Remberger M.
    Bone Marrow Transplant; 1994 Jul; 14(1):79-87. PubMed ID: 7951124
    [Abstract] [Full Text] [Related]

  • 19. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA.
    Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
    [Abstract] [Full Text] [Related]

  • 20. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
    Ancín I, Ferrá C, Gallardo D, Peris J, Berlanga J, Gonzalez JR, Virgili N, Grañena A.
    Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.